CellCarta acquires Biogazelle to strengthen its genomic capabilities and expand into digital PCR (dPCR) services
PR93673
MONTREAL, Dec. 14, 2021 /PRNewswire=KYODO JBN/ --
-- This acquisition solidifies CellCarta's leadership position in genomic
services with a unique combination of assay development and global clinical
trial sample analysis capabilities covering a comprehensive range of
established and cutting-edge genomic technologies.
CellCarta, a leading global provider of precision medicine laboratory services,
announced today the acquisition of Biogazelle ("Biogazelle"), a leader in
genomic testing solutions. Located in Ghent (Belgium), Biogazelle develops and
deploys high-end digital PCR (dPCR), quantitative PCR (qPCR) and RNASeq assays
for its pharmaceutical and biotech industry clients.
Logo - https://mma.prnewswire.com/media/1708958/CellCarta_1.jpg
Logo - https://mma.prnewswire.com/media/1708959/CellCarta_Biogazelle_2.jpg
With decades of experience in gene expression analysis, the Biogazelle team is
uniquely positioned and skilled in the application of quantitative PCR and
digital PCR. Co-founders Jan Hellemans and Jo Vandesompele are internationally
recognized for setting standards in gene expression analysis. Biogazelle, a
Ghent University spin-off with the financial support of BNP Paribas Fortis and
the investment funds of Qbic, PMV and the Fournier-Majoie Foundation, was the
first European laboratory to offer the dPCR technology and is still at the
forefront of dPCR-based research. The group also provides dedicated RNA
sequencing workflows on clinical samples such as liquid biopsies and FFPE
tissues.
"Biogazelle's exceptional genomics expertise will enable CellCarta to further
support its clients' therapeutic development strategies, offering them key
solutions to address their clinical challenges and move their immunology and
other programs forward" said Martin LeBlanc, CEO of CellCarta. Acquiring
Biogazelle strengthens CellCarta's growth strategy to become the leading
provider of precision medicine services and will allow the organization to
extend genomic services from discovery to clinical settings. "We are very
excited to join forces with CellCarta. With both organizations driven by
scientific excellence and innovation, it's the logical next step for us to
maximally leverage our know-how and services on a truly global scale." said
Roel Sterken, CEO of Biogazelle.
While continuing to offer its current breadth of genomic services, Biogazelle
will become CellCarta's Center of Excellence for the development of complex
genomic biomarker assays. The acquisition allows CellCarta to expand its
offering to clients in fields with high demand in genomic analysis, such as
immuno-oncology and cell and gene therapy.
About CellCarta
CellCarta is a leading provider of specialized precision medicine laboratory
services to the biopharmaceutical industry. Leveraging its integrated
analytical platforms in immunology, histopathology, proteomics and genomics, as
well as related specimen collection and logistics services, CellCarta supports
the entire drug development cycle, from discovery to late-stage clinical
trials. The company operates globally with 10 facilities located in Canada,
USA, Belgium, Australia, and China.
For more information: cellcarta.com
About Biogazelle
Biogazelle offers expert laboratory services in nucleic acid quantification
(gene expression, mutation and copy number analysis, antisense oligonucleotide
screening) to support its customers in their development of diagnostics and
therapeutics. Customized workflows for clinically relevant samples – from
liquid biopsies to fixed tissues – are available. In addition, Biogazelle's
advanced RNA biomarker development program offers an end- to-end solution from
RNA biomarker panel discovery (including liquid biopsies) to the development of
a PCR-based molecular diagnostic test. Biogazelle also serves as a specialty
lab in the field of clinical trials and in routine diagnostic settings.
For more information: biogazelle.com
Media Contact for CellCarta: Prosek Partners, Jackie Schofield,
Jschofield@prosek.com; CellCarta, Guylaine Galipeau, Global Marketing Director,
CellCarta, ggalipeau@caprion.com; Biogazelle, Roel Sterken, CEO, Biogazelle,
+32/470.888.700, Roel.sterken@biogazelle.com
SOURCE CellCarta
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。